FREDERICK, Md., Jan. 24 /PRNewswire-FirstCall/ -- BioElectronics Corporation, , announced today the addition of Jeffrey Weinzweig, MD and W. Thomas McClellan, MD, of the Lahey Clinic in Boston, Massachusetts, to the company’s Medical Advisory Board. Drs. Weinzweig and McClellan have been elected to the company’s Medical Advisory Board to facilitate the collaboration of clinical studies using the renowned Lahey Clinic (Burlington, MA) and to assist with the research and development of the company’s ActiPatch(TM) Therapy products.
Dr. Jeffrey Weinzweig, Chairman of the Department of Plastic Surgery for the Lahey Clinic, joins the board with a long history of clinical research, surgical experience and medical education. Dr. Weinzweig has authored more than a hundred and fifty scientific papers and chapters on various topics within the plastic surgery, hand surgery and craniofacial surgery arena and is currently editing his fifth textbook. He also serves as Director of the Institute of Craniomaxillofacial Surgery and Director of Research of the Craniofacial Biology & Tissue Engineering Laboratory at Lahey and has lectured to medical professionals around the world.
Dr. W. Thomas McClellan, Chief Plastic Surgery Resident at the Lahey Clinic, also joins the committee with a long-standing reputation for excellence in medicine. In addition to serving as chief resident, Dr. McClellan has also authored numerous scientific papers and been awarded such prestigious honors as 2002, 2003 and 2004 Resident Physician Teacher of the Year from West Virginia School of Medicine and admission into Alpha Omega Alpha Honor Medical Society.
“We are thrilled and quite fortunate to have these two esteemed surgeons join our team. We look forward to having their insight and talents enhance our mission in the clinical study of our break through technology,” said Bioelectronics’ Executive Vice President and Chief Operating Officer Thomas O’Connor.
“To have such talent as Drs. Weinzweig and McClellan join our board speaks volumes about ActiPatch(TM) and the scientific advancements being generated at BioElectronics. I look forward to working with them in these important endeavors,” said BioElectronics’ Medical Advisory Board Chairman Lawrence L. Michaelis, MD.
The appointments are effective immediately.
ActiPatch(TM) is a drug-free, anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch(TM) delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.
For more information visit http://www.bioelectronicscorp.com
Safe Harbor Statement:
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
BioElectronics Corporation
CONTACT: Andrew J. Whelan, President & CEO, or Thomas O’Connor, EVPOperations & COO, both of BioElectronics Corporation, +1-301-644-3906, Fax:+1-301-644-3939, or info@bioelectronicscorp.com
Web site: http://www.bioelectronicscorp.com/
